One life gone. Now, another. By the end of today, the Centers for Disease Control and Prevention predict that, on average, 115 Americans will die from an opioid overdose. The cycle will repeat tomorrow and the next day as well as the next.
What was once a chilling feeling has turned numb, leaving the public unphased by the steadily increasing body count scattered across the headlines.
(more…)
A patient’s journey as they navigate and choose from the many treatments and options available to them is highly unique. The sheer number of variables can be overwhelming. Aggregate patient journey information is locked in APLD (anonymous patient level data) sources like claims, prescription, and EMR data sets. Logically sifting through multiple multi-billion row data sets looking for actionable insights is important for today’s pharmaceutical manufacturers. It requires the most leading edge possible data infrastructures to handle at scale.
(more…)
For decades, Pharmaceutical data analytics has been a largely manual and tedious task conducted by the commercial research, health outcomes, R&D and Clinical Study groups at Pharma companies both small and large. With the emergence of machine learning, artificial intelligence and other disruptive innovations, Pharma, like other industries has also started its slow but sure transition to a more agile, data-driven model – one where in-house research is supplemented by intelligence gathered by applying algorithms across terabytes of Physician Rx, Patient Claims and other related datasets.
(more…)
As each industry becomes more technologically savvy, the pharmaceutical industry has the chance to emerge into the 21st century and reform how they treat patients while tackling different medical epidemics that affect the world today.
(more…)
